Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annu...( MOUNTAIN VIEW Calif. May 1 /- Ale...),Health

MOUNTAIN VIEW, Calif., May 1 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present at the 161st American Psychiatric Association annual meeting the results of a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the treatment of acute agitation in schizophrenic patients. The poster presentation, "Inhaled Loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients" (Presentation NR5-032), will be available for viewing at the meeting at the Washington Convention Center in Washington, D.C. on Tuesday, May 6, 2008 from 3:00 to 5:00 p.m. Eastern Time.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Prod
'/>"/>